JP7795454B2 - （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法 - Google Patents

（ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Info

Publication number
JP7795454B2
JP7795454B2 JP2022521584A JP2022521584A JP7795454B2 JP 7795454 B2 JP7795454 B2 JP 7795454B2 JP 2022521584 A JP2022521584 A JP 2022521584A JP 2022521584 A JP2022521584 A JP 2022521584A JP 7795454 B2 JP7795454 B2 JP 7795454B2
Authority
JP
Japan
Prior art keywords
treatment period
human patient
itp
platelet count
prior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550919A (ja
JPWO2021076514A5 (https=
JP2022550919A5 (https=
Inventor
スティーブン・グーレイ
アン・ニーレ
フィリップ・ナン
クレア・ラングリッシュ
オルガ・バンドマン
ドルカ・トーマス
Original Assignee
プリンシピア バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリンシピア バイオファーマ インコーポレイテッド filed Critical プリンシピア バイオファーマ インコーポレイテッド
Publication of JP2022550919A publication Critical patent/JP2022550919A/ja
Publication of JPWO2021076514A5 publication Critical patent/JPWO2021076514A5/ja
Publication of JP2022550919A5 publication Critical patent/JP2022550919A5/ja
Priority to JP2025129327A priority Critical patent/JP2025163155A/ja
Application granted granted Critical
Publication of JP7795454B2 publication Critical patent/JP7795454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022521584A 2019-10-14 2020-10-13 （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法 Active JP7795454B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025129327A JP2025163155A (ja) 2019-10-14 2025-08-01 （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962914688P 2019-10-14 2019-10-14
US62/914,688 2019-10-14
US201962951302P 2019-12-20 2019-12-20
US62/951,302 2019-12-20
PCT/US2020/055410 WO2021076514A1 (en) 2019-10-14 2020-10-13 Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025129327A Division JP2025163155A (ja) 2019-10-14 2025-08-01 （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Publications (4)

Publication Number Publication Date
JP2022550919A JP2022550919A (ja) 2022-12-05
JPWO2021076514A5 JPWO2021076514A5 (https=) 2023-10-20
JP2022550919A5 JP2022550919A5 (https=) 2023-10-20
JP7795454B2 true JP7795454B2 (ja) 2026-01-07

Family

ID=73040359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521584A Active JP7795454B2 (ja) 2019-10-14 2020-10-13 （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法
JP2025129327A Pending JP2025163155A (ja) 2019-10-14 2025-08-01 （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025129327A Pending JP2025163155A (ja) 2019-10-14 2025-08-01 （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Country Status (12)

Country Link
US (3) US20210106584A1 (https=)
EP (1) EP4045051A1 (https=)
JP (2) JP7795454B2 (https=)
KR (1) KR20220080179A (https=)
CN (1) CN115209899A (https=)
AU (1) AU2020365951A1 (https=)
CA (1) CA3154257A1 (https=)
CO (1) CO2022006087A2 (https=)
IL (1) IL291994A (https=)
MX (1) MX2022004427A (https=)
TW (2) TWI877239B (https=)
WO (1) WO2021076514A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45547A (fr) 2016-06-29 2019-05-08 Principia Biopharma Inc Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
JP2023511105A (ja) 2020-01-22 2023-03-16 プリンシピア バイオファーマ インコーポレイテッド ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
AU2022257016A1 (en) * 2021-04-16 2023-11-30 Principia Biopharma, Inc. Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds
TW202432135A (zh) * 2022-10-31 2024-08-16 美商普林斯匹亞生物製藥公司 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－氧雜環丁－３－基）哌𠯤－１－基］戊－２－烯腈治療免疫性血小板減少症的方法
AU2024306785A1 (en) * 2023-06-30 2026-02-19 Principia Biopharma Inc. Methods for treating persistent or chronic immune thrombocytopenia in children, adolescents and adults by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527401A (ja) 2012-09-10 2015-09-17 プリンシピア バイオファーマ インコーポレイテッド キナーゼ阻害剤としてのピラゾロピリミジン化合物
JP2017506246A (ja) 2014-02-20 2017-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535721A1 (fr) 1982-11-08 1984-05-11 Sanofi Sa Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2518353B2 (ja) 1988-06-09 1996-07-24 住友化学工業株式会社 シアノ酢酸アミド誘導体およびその製造中間体
CA2018801C (en) 1990-06-12 2000-08-22 Pierre Louis Beaulieu Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
JPH04177244A (ja) 1990-11-10 1992-06-24 Konica Corp ハロゲン化銀写真感光材料
CA2033447C (en) 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH05301838A (ja) 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
JPH0827090A (ja) 1994-05-13 1996-01-30 Sumitomo Chem Co Ltd シアノ酢酸アミド誘導体、その用途およびその製造中間体
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
IL131581A (en) 1997-03-14 2003-12-10 Basf Ag Cycloalkylalkanecarboxamides, their production and fungicide compositions comprising them
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
IL125947A0 (en) 1997-09-17 1999-04-11 American Cyanamid Co 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
DE69814122T2 (de) 1997-10-09 2004-03-18 Dexcel Pharma Technologies Ltd. Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
JP3991812B2 (ja) 2001-12-11 2007-10-17 住友化学株式会社 エステル化合物およびその用途
WO2003068157A2 (en) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
GB0219024D0 (en) 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
JP2006518368A (ja) 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US7285562B2 (en) 2003-08-01 2007-10-23 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
KR20090080143A (ko) 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
WO2005023773A1 (en) 2003-09-04 2005-03-17 Pfizer Limited Process for the preparation of substituted aryl pyrazoles
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
BRPI0414798A (pt) 2003-09-25 2006-11-21 Warner Lambert Co métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
JP4552456B2 (ja) 2004-02-27 2010-09-29 住友化学株式会社 エステル化合物およびその用途
WO2005085210A1 (ja) 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
US7807719B2 (en) 2004-09-14 2010-10-05 Chaim Roifman Compounds useful for modulating abnormal cell proliferation
WO2006036941A2 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1863449A2 (en) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
DE602006012042D1 (de) 2005-06-15 2010-03-18 Pfizer Ltd Substituierte arylpyrazole zur verwendung gegen parasiten
US20070149464A1 (en) 2005-06-15 2007-06-28 Pfizer Inc. Combination
US20080146643A1 (en) 2005-06-15 2008-06-19 Pfizer Limited Combination
US20080176865A1 (en) 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
GB0517205D0 (en) 2005-08-22 2005-09-28 Novartis Ag Organic compounds
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
ES2432361T3 (es) 2005-12-02 2013-12-03 Bayer Healthcare, Llc Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
BRPI0709916B8 (pt) 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
WO2008005954A2 (en) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
JP2010519178A (ja) 2006-11-23 2010-06-03 ノバルティス アーゲー ピリミジン類およびｃｘｃｒ２受容体アンタゴニストとしてのその使用
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
GB2447933A (en) 2007-03-27 2008-10-01 Chemence Ltd Cyanoacrylate monomer for forming an adhesive polymer
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
JP5368485B2 (ja) 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
WO2009140128A2 (en) 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
EP2310389B1 (en) 2008-05-22 2012-01-04 Amgen Inc. Heterocycles as protein kinase inhibitors
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US20110165183A1 (en) 2008-08-01 2011-07-07 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
US20100113520A1 (en) 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
EP2475375A4 (en) 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CA2781056A1 (en) 2009-11-16 2011-05-19 Rebecca Maglathlin Kinase inhibitors
CA2799904A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
BR112012030711B1 (pt) 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN101880243A (zh) 2010-06-04 2010-11-10 贵阳柏丝特化工有限公司 一种含氟氰拟除虫菊酯化合物及其合成方法与用途
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
MX382354B (es) 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
CA2840413A1 (en) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Methods and compositions for inhibition of bone resorption
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
JP2014522860A (ja) 2011-07-19 2014-09-08 メルク・シャープ・アンド・ドーム・ベー・フェー Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
WO2013059738A2 (en) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
US20150209432A1 (en) 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
JP6178861B2 (ja) 2012-11-02 2017-08-09 ファイザー・インク ブルトン型チロシンキナーゼ阻害剤
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
KR20150099588A (ko) 2012-12-20 2015-08-31 더 펜 스테이트 리서어치 파운데이션 암의 치료와 관련된 방법 및 조성물
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2014171542A1 (ja) 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
MX2016009403A (es) 2014-02-03 2016-09-16 Cadila Healthcare Ltd Compuestos heterociclicos.
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
DK3236943T3 (da) 2014-12-24 2023-04-11 Principia Biopharma Inc Sammensætninger til ileo-jejunal lægemiddeladministration
CA2971109C (en) 2014-12-24 2024-07-02 Principia Biopharma Inc. SITE-SPECIFIC DOSAGE OF A BTK INHIBITOR
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
MA45547A (fr) 2016-06-29 2019-05-08 Principia Biopharma Inc Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
CN110483521B (zh) 2018-05-14 2022-06-07 杭州和正医药有限公司 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
JP2023511105A (ja) 2020-01-22 2023-03-16 プリンシピア バイオファーマ インコーポレイテッド ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527401A (ja) 2012-09-10 2015-09-17 プリンシピア バイオファーマ インコーポレイテッド キナーゼ阻害剤としてのピラゾロピリミジン化合物
JP2017506246A (ja) 2014-02-20 2017-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood，2017年，130(Suppl.1):1052
Clinical Trials.gov_NCT03395210，2019年07月30日，<https://clinicaltraials.gov/ct2/show/NCT03395210>

Also Published As

Publication number Publication date
CA3154257A1 (en) 2021-04-22
TW202543647A (zh) 2025-11-16
JP2022550919A (ja) 2022-12-05
JP2025163155A (ja) 2025-10-28
US20250221999A1 (en) 2025-07-10
US12178818B2 (en) 2024-12-31
CO2022006087A2 (es) 2022-07-29
US20230124267A1 (en) 2023-04-20
TW202128175A (zh) 2021-08-01
EP4045051A1 (en) 2022-08-24
KR20220080179A (ko) 2022-06-14
TWI877239B (zh) 2025-03-21
US20210106584A1 (en) 2021-04-15
IL291994A (en) 2022-06-01
CN115209899A (zh) 2022-10-18
AU2020365951A1 (en) 2022-06-02
WO2021076514A1 (en) 2021-04-22
MX2022004427A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
JP7795454B2 (ja) （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法
UA124269C2 (uk) Застосування антагоністу il-13 для лікування атопічного дерматиту
US20250255874A1 (en) Methods for Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enentrile
TW202133877A (zh) 全身性紅斑狼瘡中之ｉ型干擾素抑制
JP2023542878A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
JP2025157438A (ja) （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することによる天疱瘡を処置する方法
KR102859911B1 (ko) IgE-매개 알레르기성 질환들의 치료
US20230340110A1 (en) Dosages
TW202434633A (zh) 治療甲狀腺眼疾之方法
JP2025541153A (ja) リルザブルチニブを投与することによる認知障害を有する対象における免疫性血小板減少症の治療方法
KR20260033556A (ko) (r)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여함으로써 아동, 청소년 및 성인에서 지속성 또는 만성 면역 혈소판감소증을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251219

R150 Certificate of patent or registration of utility model

Ref document number: 7795454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150